Browsed by
Tag: Application

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

On-monitor to initiate Phase 2 demo in Q1 2023 NEW YORK, Dec. 29, 2022 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a affected individual-focused biopharmaceutical company, these days announced that the U.S. Food stuff and Drug Administration (Food and drug administration) has accepted an Investigational New Drug (IND) software for the firm’s HT-001 therapeutic for the treatment for rash and pores and skin issues associated with epidermal growth factor receptor (EGFR) inhibitor treatment. EGFR inhibitors are critical therapeutic agents for the remedy…

Read More Read More

A digital application and augmented physician rounds reduce postoperative pain and opioid consumption after primary total knee replacement (TKR): a randomized clinical trial | BMC Medicine
A digital application and augmented physician rounds reduce postoperative pain and opioid consumption after primary total knee replacement (TKR): a randomized clinical trial | BMC Medicine

A digital application and augmented physician rounds reduce postoperative pain and opioid consumption after primary total knee replacement (TKR): a randomized clinical trial | BMC Medicine

Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–76. Article  PubMed  Google Scholar  Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ. 2017;359:j4792. Article  PubMed  Google Scholar  Hirschfeld DJ. Trump Declares Opioid Crisis a ‘Health Emergency’ Requests no Funds The New York Times; 2017. Google Scholar  Hollmann MW, Rathmell JP, Lirk P….

Read More Read More

UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

Veru Inc. MIAMI, July 25, 2022 (Globe NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical firm concentrated on developing novel medicines for COVID-19 and other viral and ARDS-related ailments and for the administration of breast and prostate cancers, these days declared that the United Kingdom’s (UK’s) Medicines and Healthcare Solutions Regulatory Agency (MHRA) considers that the currently available security and efficacy info will assist an expedited overview of the promoting authorization application for the Company’s sabizabulin treatment method in hospitalized…

Read More Read More